GRAIL Q2 volume-led growth continues, but PMA and reimbursement milestones remain critical

What happened

GRAIL’s second-quarter revenue rose on the back of higher Galleri test volumes, echoing the 39% volume increase seen in Q3 2025, though ASP pressure likely persisted. Management reaffirmed efforts to secure FDA approval, expand its commercial salesforce, and build international distribution partnerships, in line with the catalyst path outlined in our master report. The company’s cash burn, while improving sequentially, still generated an operating loss of over $125 million in the previous quarter, underscoring the distant path to profitability. The investment thesis remains anchored on binary outcomes: PMA acceptance/approval and broad Medicare/commercial reimbursement, neither of which is de-risked by this update. With no formal revenue guidance and liquidity providing a multi-year runway, the narrative is one of steady execution against a high-stakes regulatory backdrop.

Implication

Investors should take comfort in the consistent test volume ramp, which demonstrates real-world demand and supports the technology’s potential. However, the lack of coverage guarantees and the fluid LDT regulatory environment mean that revenue growth alone won’t bridge the gap to breakeven; ASPs remain under pressure and operating leverage is still years away. The positive Q2 call and international expansion plans align with our medium-term catalyst expectations, but they do not alter the binary nature of the upcoming PMA and reimbursement decisions. With a current market cap around $2.7 billion and negative free cash flow, valuation already assumes significant future success, leaving limited room for disappointment. We reiterate our HOLD rating, advising investors to monitor PATHFINDER-2 and NHS-Galleri readouts, PMA submission progress, and any payer coverage developments as the key triggers for a rating change.

Thesis delta

The Q2 update confirms Galleri volume momentum and commercial expansion efforts in line with our base case. No material change to the investment thesis; the critical PMA and reimbursement catalysts remain unresolved, sustaining our HOLD rating with the same watch triggers.